The future of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy

Bone Marrow Transplantation

Volumn 38, Issue 11, 2006, Pages 711-714

  Ueno, N T ^a   Cheng, Y C ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; FLUDARABINE; INTERLEUKIN 2; SORAFENIB; SUNITINIB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASTHENIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; DEPRESSION; EDITORIAL; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; METASTASIS; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE;

CARCINOMA, RENAL CELL; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33751069330     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705523     Document Type: Editorial

References (27)

1. Linehan WM, Zbar B, Bates SE, Zelefsky MJ, Yang JC. Cancer of the kidney and ureter. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. J.B. Lippincott Co.: Philadelphia, 2001, pp 1362-1384.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-875.
3. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044-2049.
4. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
5. Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: A pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409-2415.
6. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
7. Hentschke P, Barkholt L, Uzunel M, Mattson J, Wersall P, Pisa P et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253-261.
8. Baron F, Frere P, Baudoux E, Sautois B, Fillet G, Bequin Y. Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. Haematologica 2003; 88: 479-480.
9. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
10. Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
11. Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up. Exp Hematol 2004; 32: 599-606.
12. Massenkeil G, Roigas J, Nagy M, Wille A, Stroszczynski C, Mapara MY et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: Delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 2004; 34: 309-316.
13. Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: Toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004; 10: 7799-7811.
14. Rini BI, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol 2001; 165: 1208-1209.
15. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017-2024.
16. Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant 2005; 35: 253-260.
17. Rzepecki P, Zolnierek J, Sarosiek T, Langiewicz P, Szczylik C. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma - single center experience. Neoplasma 2005; 52: 238-242.
18. Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T et al. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: A CALGB intergroup phase II study. Biol Blood Marrow Transplant 2006; 12: 778-785.
19. Aoyama Y, Nakamae H, Yamamura R, Makita K, Shima E, Ohta K et al. Reduced-intensity stem cell transplantation in two cases of metastatic renal cell carcinoma. Int J Urol 2003; 10: 610-614; discussion 615.
20. Bornhauser M, Klenk U, Rollig C, Haack M, Babatz J, Koch O et al. Mixed response after allogeneic haemopoietic-cell transplantation for metastatic renal-cell carcinoma. Lancet Oncol 2004; 5: 191-192.
21. Takami A, Asakura H, Koshida K, Namiki M, Nakao S. Reduced-intensity allogeneic stem cell transplantation for renal cell carcinoma: In vivo evidence of a graft-versus-tumor effect. Haematologica 2004; 89: 375-376.
22. Secondino S, Pedrazzoli P, Giannetta L, Schiavetto I, Vanzulli A, Siena S. Evidence of graft-versus-tumour effect following allogeneic haematopoietic stem cell transplantation in renal cancer other than clear cell type. Bone Marrow Transplant 2004; 34: 917-918.
23. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal cell carcinoma in Europe. Ann Oncol 2006; 17: 1134-1140.
24. Takami A, Takamatsu H, Yamazaki H, Ishiyama K, Okumura H, Ohata K et al. Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: First evidence of cord-blood-versus-solid-tumor effect. Bone Marrow Transplant 2006; 38: 729-732.
25. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc ASCO 2005; 23: 380s (abstract).
26. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
27. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.